The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

Year in Review: Lung Cancer

Balazs Halmos

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Vogl,NY on How to Ask Good Questions at Medical Meetings

Vogl, NY

S. Vogl

Cancer Screening Molecular Tools

Fengting Yan

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

Staging Disease: How Oncologists Stage NSCLC

GRACE

I. Dagogo-Jack, M. Das, C. Jeffrey Yang

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

2024 ASCO® Annual Meeting Insights Hub

L. Raez

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical Implicat…

Insights from 2023 ASCO® Annual Meeting

J. West

2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertini…

Yale Cancer Center

P. Janne

NSCLC & Targeted Therapy: A Brief Overview and Update in the Metasta…

Memorial Sloan Kettering Cancer Center

M. Hwang

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

2024 ASCO® Annual Meeting Insights Hub

V. Subbiah

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles